HPS Pharmacies wish to give notice that Bristol-Myers Squibb will be removing Baraclude® from the Pharmaceutical Benefits Scheme (PBS) as follows:
Baraclude® tablets will no longer be subsidised on the PBS from 1 July 2021. There are a number of equivalent generic brands of entecavir tablets which will remain on the PBS. The removal of Baraclude® is not related to any safety or efficacy issues.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Bristol-Myers Squibb on 1800 629 273, or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates